(SBFM) Sunshine Biopharma, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SBFM) Sunshine Biopharma, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Sunshine Biopharma, Inc. 4P's Marketing Mix Analysis summarizes the company’s product offerings, pricing approach, distribution channels, and promotional tactics to show how it competes in the biotech market; the page includes a real preview/sample of the analysis so you can assess style and content before buying—purchase the full version to get the complete ready-to-use report.
Product
Adva-27a lead oncology candidate
Adva-27a is Sunshine Biopharma’s flagship anticancer asset: a GEM-difluorinated C-glycoside derivative of podophyllotoxin built for broad oncology use. It anchors the Product strategy with one lead program aimed at multiple tumor types, while current product revenue is still nil because the asset remains in development.
10 cancer types targeted
Sunshine Biopharma, Inc.'s candidate spans 10 cancer types: leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver. That is a wide 10-indication profile for one asset and supports a multi-indication R&D strategy. It matters because global cancer burden remains huge, with about 20 million new cases and 9.7 million deaths in 2022, so broad reach can widen the commercial upside.
Multidrug-resistant tumor activity
Adva-27a is reported to target multidrug-resistant tumor cells, including pancreatic, breast, small-cell lung, and uterine sarcoma models, which broadens its scientific fit across 4 hard-to-treat cancer types. That matters because drug resistance drives relapse in a large share of advanced cancers, and a clear resistant-cell signal can strengthen the product's value story. For Sunshine Biopharma, Inc., this can support higher R&D interest and stronger partnering appeal.
SBFM-PL4 anti-coronavirus candidate
Sunshine Biopharma, Inc. is advancing SBFM-PL4 as an anti-coronavirus treatment, with a University of Georgia collaboration supporting the program. The asset gives Company Name a second therapeutic pillar beyond oncology, which can broaden pipeline risk and future revenue options. One pipeline, two disease areas.
- Anti-coronavirus candidate
- University of Georgia support
- Second pillar beyond oncology
Essential 9 and Calcium-Vitamin D supplements
Sunshine Biopharma, Inc. also sells nutritional products, including the Essential 9 tablet and an Essential Calcium-Vitamin D supplement. In 2025, these 2 consumer items help diversify revenue beyond drug development and give the Company a wider, lower-regulated sales base.
From a product view, the line is simple and mass-market: one multi-nutrient tablet and one bone-health supplement. That mix supports repeat purchase behavior, broader retail appeal, and cross-selling across wellness buyers.
These products also reduce reliance on a single pharma pipeline, which matters when R&D timelines are long and capital needs stay high. The consumer-health angle can add steadier demand while the core drug business advances.
- 2 nutritional products in the line
- Diversifies beyond drug development
- Targets recurring consumer demand
R&D-Heavy Mix, with Consumer Products Funding Today
Sunshine Biopharma, Inc.'s product mix is still R&D-heavy, led by Adva-27a, a 10-indication oncology asset, plus SBFM-PL4 for coronavirus and 2 nutritional products. In 2025, consumer items provide the only current sales base, while drug programs still carry no product revenue.
| Product | 2025 status | Key point |
|---|---|---|
| Adva-27a | Development | 10 cancer types |
| SBFM-PL4 | Development | Anti-coronavirus |
| Nutritional products | Revenue | 2 SKUs |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Sunshine Biopharma, Inc.’s Product, Price, Place, and Promotion strategy, grounded in real-world market context.
Editable Excel File
Distills Sunshine Biopharma’s 4Ps into a quick, practical view that helps teams spot gaps and align faster.
Reference Sources
Lists primary, reputable sources so investors can verify Sunshine Biopharma assumptions fast with a clear, traceable reference trail.
Place
Pointe-Claire, Canada headquarters
Sunshine Biopharma’s headquarters in Pointe-Claire, Quebec, serves as the company’s main corporate base and anchors its North American operations. The location supports a Canada-U.S. business footprint for its biotech and supplement lines. As a Montreal-area hub, it sits in a region with over 4.3 million people in the Greater Montreal area, helping the company stay close to talent and logistics.
University of Georgia research link
Sunshine Biopharma, Inc.'s SBFM-PL4 program is backed by a University of Georgia partnership, putting part of its research base in the U.S. The University of Georgia reported about $628.1 million in research expenditures in FY2024, which adds scale and scientific depth. This academic link strengthens credibility and helps widen the program's reach.
Pharmaceutical development footprint
Sunshine Biopharma, Inc. operates as a pharmaceutical company, and its development footprint is centered on oncology and antiviral research. That puts its core work inside biotech R&D, where value comes from pipeline progress, preclinical data, and clinical milestones. In this place, success depends on turning lab science into drug candidates with clear disease targets.
Nutritional product market access
Sunshine Biopharma, Inc. sells dietary supplements and drug candidates, so Nutritional product market access spans both consumer wellness and research channels. That mix widens reach beyond prescription demand and supports sales into nutrition-oriented outlets while drugs stay in development. The model serves two markets at once: therapeutic and preventive wellness.
- Consumer wellness and research access
- Dietary supplements plus drug pipeline
- Two-market positioning broadens reach
North American operating base
Sunshine Biopharma's North American operating base spans 2 key hubs: a Canadian headquarters and a U.S. research collaboration. That cross-border setup supports regulatory work, lab access, and commercial outreach in 2 of the region's biggest pharma markets. It also helps the Company serve both biotech and broader healthcare customers.
- 2-country North American footprint
- Supports regulatory and scientific work
- Helps reach multiple market segments
Sunshine Biopharma’s Canada-U.S. Base Powers Growth
Sunshine Biopharma’s Place is centered on Pointe-Claire, Quebec, giving it a Canada-U.S. base for operations, compliance, and distribution. Its University of Georgia research link adds U.S. lab reach, while Greater Montreal’s 4.3 million people support hiring and logistics. The setup fits a two-market model: supplements and drug candidates.
| Place factor | Data |
|---|---|
| HQ | Pointe-Claire, Quebec |
| Research link | University of Georgia |
| Market base | Canada-U.S. |
| Metro reach | 4.3M+ |
Full Version Awaits
Sunshine Biopharma, Inc. Reference Sources
The preview shown here is the actual Sunshine Biopharma, Inc. 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it covers Product, Price, Place, and Promotion with practical insights and editable recommendations.
Promotion
University of Georgia collaboration
Sunshine Biopharma, Inc. University of Georgia collaboration is a clear promotional asset because it adds outside scientific validation to SBFM-PL4. Academic backing can lift trust with investors and the public, especially for a preclinical asset moving from lab work toward broader visibility. One university partnership can carry more credibility than paid promotion alone.
Broad-spectrum cancer pipeline
Sunshine Biopharma, Inc. can market Adva-27a as one candidate with a multi-cancer profile, so one message can cover several malignancies at once. That broad scope helps the Company stand out in a crowded oncology field, where single-target programs are common. The pitch is simple: one pipeline asset, wider possible use, clearer differentiation.
Multidrug-resistance angle
Sunshine Biopharma, Inc. can frame multidrug resistance as a core promotion point because resistant cancer cells drive many relapses and chemo failures, and the global cancer burden is still huge, with about 20 million new cases and 9.7 million deaths in 2022. This "hard-to-treat" angle speaks to a high-need, high-value market. A product that targets resistant cells can stand out in oncology, where response durability matters as much as initial shrinkage.
Anti-coronavirus development story
SBFM-PL4 gives Sunshine Biopharma, Inc. a second headline research program, so the story is no longer tied only to cancer. That antiviral angle can widen media and stakeholder reach because it speaks to a bigger public-health market, not just oncology. Two visible programs can also make the Company easier to follow for investors and press.
- 2 headline programs now stand out
- Antiviral work broadens relevance
- More angles for media attention
Science-based supplement branding
Sunshine Biopharma, Inc. frames its nutrition products as scientifically formulated, which supports a credibility-first message in a supplement market where trust drives repeat buying. That fits its biotech identity and helps the brand stand apart from lifestyle-led rivals.
It also gives the Promotion mix a clear proof point: science, not just wellness claims. That makes the supplement line feel more consistent with a research-led Company Name.
- Science-led branding builds trust
- Matches biotech positioning
- Supports premium credibility
Sunshine Biopharma Touts Science-Led Cancer Pipeline and Trust Brand
Sunshine Biopharma, Inc. uses science-led promotion: University of Georgia backing adds credibility to SBFM-PL4, while Adva-27a is pitched as a multi-cancer candidate. The Company also leans on the global cancer load of 20 million new cases and 9.7 million deaths in 2022 to frame unmet need. Its nutrition line extends the message into a trust-based consumer market.
| Promotion cue | Data point |
|---|---|
| Global cancer burden | 20 million cases; 9.7 million deaths, 2022 |
| Headline programs | Adva-27a, SBFM-PL4 |
| Promotion angle | Science-led, multi-asset |
Price
Adva-27a price not disclosed
No commercial price is disclosed for Adva-27a, and the asset is still in development, so market pricing has not been set. Any future price will depend on regulatory approval, launch timing, and reimbursement terms. For now, Sunshine Biopharma, Inc. is positioned at a pre-commercial stage, so pricing remains undefined.
SBFM-PL4 price not disclosed
No public price is disclosed for SBFM-PL4. Sunshine Biopharma, Inc. is still developing it as an anti-coronavirus treatment, so pricing cannot be set until clinical and regulatory results are known. Any future price will likely depend on trial data, approval status, and market access terms.
Essential 9 price not provided
The available information does not list a retail price for Essential 9, so Sunshine Biopharma, Inc. has not disclosed a public amount for this nutritional product. A current product listing is needed to verify pricing, since online supplement prices can vary widely by pack size and seller. Without a posted price, the price strategy looks undisclosed rather than fixed.
Calcium-Vitamin D price not provided
The Essential Calcium-Vitamin D supplement has no stated price in the source information, so Sunshine Biopharma, Inc. does not show public consumer pricing here. That makes the product’s price point impossible to verify from this material alone.
A current retail channel or live e-commerce listing is needed to confirm the actual shelf price, pack size, and any discounting.
- Price not disclosed in source
- Consumer pricing not visible
- Retail check needed
Companywide list prices unavailable
Sunshine Biopharma, Inc. does not show a companywide price sheet in the supplied details, so no single list price can be verified. Because its portfolio mixes investigational drugs and consumer supplements, pricing can differ by product stage, channel, and market.
No verified July 2026 public pricing is shown here, so any price read must be product specific.
- Companywide list prices unavailable
- Pricing varies by product stage
- No verified July 2026 public pricing
Sunshine Biopharma Pricing Remains Unclear
Sunshine Biopharma, Inc. does not disclose a public list price for Adva-27a or SBFM-PL4, and both remain pre-commercial, so pricing is still undefined. Its supplement items, including Essential 9 and Essential Calcium-Vitamin D, also show no verified retail price in the supplied source. So the Price strategy is product specific, stage driven, and not yet transparent.
| Product | Price status |
|---|---|
| Adva-27a | No public price |
| SBFM-PL4 | No public price |
| Essential 9 | Retail price not verified |
| Essential Calcium-Vitamin D | Retail price not verified |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.